Marshall Wace, LLP Amarin Corp Plcuk Transaction History

Marshall Wace, LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$1.12 - $1.49 $105,730 - $140,658	-94,402 Reduced 42.79%	126,211 $150,000
Q1 2023 May 15, 2023	BUY	$1.19 - $2.19 $262,529 - $483,142	220,613 New	220,613 $330,000
Q2 2022 Aug 15, 2022	BUY	$1.13 - $3.69 $870,928 - $2.84 Million	770,733 Added 616.16%	895,819 $1.33 Million
Q1 2022 May 16, 2022	BUY	$2.85 - $3.73 $74,789 - $97,882	26,242 Added 26.55%	125,086 $412,000
Q2 2021 Aug 13, 2021	BUY	$4.26 - $6.5 $421,075 - $642,486	98,844 New	98,844 $433,000
Q4 2020 Feb 16, 2021	SELL	$4.04 - $5.31 $1.31 Million - $1.72 Million	-323,968 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$3.64 - $7.76 $292,732 - $624,066	80,421 Added 33.02%	323,968 $1.36 Million
Q2 2020 Aug 13, 2020	SELL	$4.78 - $8.26 $1.51 Million - $2.6 Million	-314,861 Reduced 56.39%	243,547 $1.69 Million
Q1 2020 May 15, 2020	BUY	$4.0 - $21.53 $2.12 Million - $11.4 Million	530,350 Added 1890.19%	558,408 $2.23 Million
Q4 2019 Feb 14, 2020	BUY	$13.94 - $24.12 $391,128 - $676,758	28,058 New	28,058 $602,000

177

65.1M

258K

98K

Ticker AMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 403,206,016
Market Cap $222M
Description
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.